A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers
Canada is among the highest spenders on health care in the Organization for Economic Co-operation and Development (OECD). In Canada, public insurance covers only 43% of prescription drug cost, while the remainder is paid by private payers (35%) or patients (out of pocket). In the public sector, provincial/territorial programs and federal direct drug subsidy programs are the main payers.
Fergal Mills, InnomarConsulting, contributes to a comparative review to provide a list of recommendations for revising the Canadian BIA guidelines, with applicability for both public and private plan new drug submissions in Canada.